MindBio Phase 2 LSD-Microdosing Clinical Trial In Patients With Major Depressive Disorder Begins Pre-Screening Participants

MindBio Therapeutics Corp. MBIO WF have started pre-screening for participant entry into phase 2 LSD-microdosing clinical trials. The clinical trials are a for take home use of MindBio's LSD-microdosing treatment. The initial phase 2a open label trial will assess the treatment in patients with major depressive disorder for 8 weeks.

MindBio's LSD-Microdosing clinical trials to date have yielded positive top line data such as improved quality of sleep including REM and total time of sleep and statistically significant enhancements in subjective feelings of "wellness", "creativity", "happiness", "social connectivity" and "energy". Participants in the LSD-Microdosing group also reported statistically significant feelings of being less "angry" and less "irritable".

Co-founder and CEO of MindBio Therapeutics Justin Hanka stated "We are excited to be progressing our LSD-Microdosing protocols through to phase 2 clinical trials in patients with major depressive disorder. The positive data we have collected to date is highly encouraging for targeting depressed patients with diminished mood and disrupted sleep".

Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Benzinga edit with photos by fizkes and olesea vetrila on Shutterstock

Related News

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study